• Search
  • Version for the visually impaired
  • en
  • About us
  • Structure
  • Services
  • Appeals
  • Contacts
    • Order a ticket
    +375 (17) 269-72-03
    About us
    Structure
    Medical services
    Appeals
    Contacts
    Reviews
    1. Home
    2. Services
    3. Paid services
    4. for citizens of the Republic of Belarus
    5. Laboratory diagnostics

    Laboratory diagnostics

    Price list for paid medical services

    Position #Service nameMeasurement unitTariff excluding VAT, rub.Tariff, including VAT, rubles.Cost of materials, rubles .Including VAT, RUBTotal price of the service, rubles.
    Laboratory diagnostics  
    1 Individual operations            
    1.1. pipetting            
    1.1.2. pipetting with semi-automatic pipettes pipettes 0.04 0.04 0.21   0.25
    1.2. sample reception and registration registration 0.36 0.36 0.06   0.42
    1.4. blood draw            
    1.4.1. blood sampling from a finger for hematological (research of one indicator), biochemical studies, determination of the international normalized ratio (hereinafter - INR) sample 0.36 0.36 1.79   2.15
    1.4.2. blood sampling from a finger for the entire spectrum of hematological studies in the concept of "complete blood count" sample 0.72 0.72 1.86   2.58
    1.4.3. blood draw from a vein (Standard) sample 0.80 0.80 2.55   3.35
    1.4.3. taking blood from a vein (Standard_1 (antibodies to SARS-COV-2)) sample 0.80 0.80 4.41 0.36 5.21
    1.5. processing blood to receive            
    1.5.1. processing blood to obtain serum sample 0.54 0.54 0.31   0.85
    1.5.2. processing blood to obtain plasma sample 0.54 0.54 0.31   0.85
    2 General clinical laboratory tests            
    2.1. urine analysis by manual methods            
    2.1.1. urine analysis by manual methods: determination of quantity, color, study of transparency, sediment, relative density, pH investigated 0.25 0.25 0.22   0.47
    2.1.4. protein definition:            
    2.1.4.2. urine test: pyrogall red protein determination investigated 1.00 1.00 0.45   1.45
    2.1.9. manual urine examination: microscopic examination of sediment :.            
    2.1.9.1. urinalysis: microscopic examination normal investigated 0.60 0.60 0.41   1.01
    2.1.9.2. for pathology (protein in urine) investigated 0.90 0.90 0.42   1.32
    2.1.10. urine test: counting the number of formed elements by the Nechiporenko method investigated 1.74 1.74 0.61   2.35
    2.1.11. determination of the concentration ability of the kidneys according to Zemnitsky investigated 1.50 1.50 1.69   3.19
    2.1.14. performing urine tests with analyzers:            
    2.1.14.1. urine analysis with analyzers: study of a complex of parameters of general urine analysis using semi-automatic analyzers based on "dry chemistry" methods investigated 0.57 0.57 1.33   1.90
    2.10. examination of the discharge of the genitourinary organs (from the urethra, cervical canal, vagina, prostate secretion            
    2.10.1. microscopic examination            
    2.10.1.1. study of urogenital discharge: preparations of native material investigated 0.96 0.96 0.16   1.12
    2.10.1.2. study of urogenital discharge: preparations stained with methylene blue investigated 1.65 1.65 1.54   3.19
    2.10.1.3. study of urinary tract discharge: Gram-stained preparations investigated 2.55 2.55 0.12   2.67
    2.10.2. examination of a vaginal smear for the functional state of the ovaries (epithelial cells of the vagina, karyopycnotic index, maturation index) investigated 2.32 2.32 0.71   3.03
    2.11. examination of human ejaculate            
    2.11.1. instruction on receipt and delivery of material investigated 0.49 0.49     0.49
    2.11.2. determination of physical and chemical properties of sperm investigated 0.49 0.49 0.27   0.76
    2.11.3. microscopic examination of the ejaculate            
    2.11.3.1. determination of the number of spermatozoa in Goryaev's chamber, in the bottom milliliter of ejaculate and in the entire amount of ejaculate investigated 3.18 3.18 0.09   3.27
    2.11.3.2. microscopic examination of native preparations investigated 3.18 3.18 0.15   3.33
    2.11.3.3. microscopic examination of the stained smear investigated 2.20 2.20 0.18   2.38
    2.12. postcoical test (Shuvarsky's test) and its modification investigated 2.20 2.20 0.15   2.35
    3 Hematological tests            
    3.1. blood test:            
    3.1.1. preparation of a peripheral blood sample for cytomorphic examination (making blood smears, fixation, staining)            
    3.1.1.1. Hematological blood test: manual method sample 1.80 1.80 0.13   1.93
    3.1.2. microscopic (morphological) analysis of cells in a peripheral blood preparation with a description of the formed elements (visual microscopic examination            
    3.1.2.1. no pathology investigated 1.44 1.44 0.07   1.51
    3.1.2.2. with pathological changes investigated 3.67 3.67 0.11   3.78
    3.1.7. reticulocyte count            
    3.1.7.1. supravital coloring investigated 2.93 2.93 1.44   4.37
    3.1.8. platelet count            
    3.1.8.1. in Fonio stained strokes investigated 2.70 2.70 0.17   2.87
    3.1.8.3. thrombocytogram investigated 8.56 8.56 0.17   8.73
    3.1.11. blood sample analysis using hematology analyzers            
    3.1.11.3. analysis of a blood sample using an automatic hematological analyzer with differentiation of leukacytic formula            
    3.1.11.3.1. blood sample analysis on hematology analyzers with manual sample supply investigated 0.12 0.12 1.57 0.01 1.69
    3.1.12. determination of erythrocyte sedimentation rate            
    3.1.12.1. non-automated method investigated 0.36 0.36 0.01   0.37
    4 Cytological studies            
    4.1. Cytological studies: reception and registration of biomaterial drug 0.18 0.18 0.50   0.68
    4.2. exfoliative cytology:            
    4.2.1. gynecological material            
    4.2.1.1. examination of cervical smears as part of preventive examinations (screening) staining with azure-eosin methods            
    4.2.1.1.1. two-stage microscopy system            
    4.2.1.1.1.1. microscope preparation and initial microscopic examination drug 0.72 0.72 1.03 0.01 1.75
    4.2.1.1.1.2. registration of studies with identified pathology drug 0.90 0.90     0.90
    4.2.1.1.1.3. microscopic examination of smears with pathological changes drug 2.45 2.45 0.13   2.58
    4.2.1.1.2. one-stage microscopy system            
    4.2.1.1.2.1. cytogram with the wording of the conclusion drug 1.70 1.70 1.06 0.01 2.76
    4.2.1.1.2.2. cytogram with details of the identified changes and the wording of the conclusion drug 2.65 2.65 1.11 0.01 3.76
    4.2.1.2. diagnostic tests            
    4.2.1.2.1. gynecological material from the cervix, or cervical canal, or vagina, or vulva, or IUD, or during culldocentesis drug 3.43 3.43 1.34 0.01 4.77
    4.2.1.2.2. gynecological material from the uterine cavity (staining with azure-eosin dyes) drug 4.17 4.17 1.37 0.01 5.54
    4.2.1.2.2. gynecological material from the uterine cavity (stained with hematoxylin-eosin) drug 4.17 4.17 1.45   5.62
    4.2.2. examination of scrapings and discharge            
    4.2.2.1. from the surface of erosions or ulcers, preparation or wounds, or fistulas, or from the nipple of the breast drug 3.10 3.10 1.63 0.02 4.73
    4.2.2.2. from the surface of tumor-like or pigmented formations of the skin drug 4.50 4.50 1.66 0.03 6.16
    4.3. puncture cytology            
    4.3.1. examination of punctates or smears-prints obtained with trepan biopsy, or intraoperative from formations of various localization drug          
    4.3.1.1. from the mammary, or thyroid, or prostate, or skin, or bone marrow drug 4.84 4.84 1.51 0.02 6.35
    4.3.1.2. from formations in the head and neck, or lungs, or mediastinum, or liver, or pancreas, or spleen, or gallbladder, or kidneys, or ureters, or bladder, or testes, or ovaries, or soft tissues, or bones, or drug 5.84 5.84 1.55 0.02 7.39
    4.3.2. examination of biological fluids (pleural, or ascitic, or cerebrospinal, or other) or lavage fluids (lavage water) drug 4.59 4.59 1.51 0.02 6.10
    4.4. examination of endoscopic material (staining with azure-eosin dyes) drug 4.35 4.35 1.51 0.02 5.86
    4.4. examination of endoscopic material (staining with hematoxylin-eosin) drug 4.35 4.35 6.69 0.88 11.04
    4.5. revision (consultation) of finished microslides drug 4.94 4.94 1.06   6.00
    5 Biochemistry            
    5.1. blood test            
    5.1.1. blood serum (plasma) test            
    5.1.1.2. research using multichannel biochemical automated photometers            
    5.1.1.2.1. Finite Point Studies investigated 0.39 0.39 5.74   6.13
    5.1.1.3. conducting research using multichannel biochemical autoanalyzers            
    5.1.1.3.2. average productivity (from 100 to 300 tests per hour)            
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (! Common for all b / x) investigated 0.41 0.41 2.29   2.70
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (ALT) investigated 0.41 0.41 0.22   0.63
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (Albumin) investigated 0.41 0.41 0.11   0.52
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (Alpha-Amylase) investigated 0.41 0.41 0.18   0.59
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of research results (AST) investigated 0.41 0.41 0.15   0.56
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (total protein) investigated 0.41 0.41 0.09   0.50
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (total bilirubin) investigated 0.41 0.41 0.08   0.49
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of research results (direct bilirubin) investigated 0.41 0.41 0.10   0.51
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with non-automated registration of research results (GGTP) investigated 0.41 0.41 0.21   0.62
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (glucose) investigated 0.41 0.41 0.10   0.51
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (Iron) investigated 0.41 0.41 0.18   0.59
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (potassium, sodium, calcium) investigated 0.41 0.41 4.30   4.71
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (Creatinine) investigated 0.41 0.41 0.43   0.84
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (LDH) investigated 0.41 0.41 0.29   0.70
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (Magnesium) investigated 0.41 0.41 7.69   8.10
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (Uric acid) investigated 0.41 0.41 0.16   0.57
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (Urea) investigated 0.41 0.41 0.21   0.62
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (Pancreatic Amylase) investigated 0.41 0.41 0.64   1.05
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (Triglycerides) investigated 0.41 0.41 0.22   0.63
    5.1.1.3.2.1. biochemical blood tests using multi-channel biochem analyzers of average production with manual registration of test results (inorganic phosphorus) investigated 0.41 0.41 0.19   0.60
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of medium production with manual registration of test results (high density cholesterol) investigated 0.41 0.41 1.73   2.14
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of medium production with manual registration of test results (low density cholesterol) investigated 0.41 0.41 1.73   2.14
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (total cholesterol + (U-CRB)) investigated 0.41 0.41 1.73   2.14
    5.1.1.3.2.1. biochemical blood tests using multichannel biochem analyzers of average production with manual registration of test results (Alkaline phosphatase) investigated 0.41 0.41 0.23   0.64
    5.1.2. whole blood test            
    5.1.2.1. whole blood glucose determination investigated          
    5.1.2.1.2. determination of glucose in whole blood by express method (Chemokyu glucose in whole blood) investigated 1.08 1.08 2.35   3.43
    5.2. urine test            
    5.2.1. determination of microalbumin in urine by immunoturbidimetric method investigated 3.62 3.62 5.70   9.32
    6 Studies of hemostasis            
    6.1. individual manipulations calibration and quality control of studies            
    6.1.1. processing venous blood to obtain plasma            
    6.1.1.1. processing venous blood to obtain platelet-rich plasma sample 0.54 0.54 0.32   0.86
    6.1.1.2. processing venous blood to obtain platelet-free plasma sample 0.72 0.72 0.51   1.23
    6.2. general tests            
    6.2.1. thromboelastography (computed thromboelastography)            
    6.2.1.1. thromboelastography non-automated registration of test results investigated 2.23 2.23 16.32   18.55
    6.2.1.2. thromboelastography automated registration of research results (TEG (without activator)) investigated 2.23 2.23 15.60   17.83
    6.2.1.2. thromboelastography automated registration of research results (TEG (heparin)) investigated 2.23 2.23 11.90   14,13
    6.2.1.2. thromboelastography automated registration of research results (TEG with kaolin) investigated 2.23 2.23 11.42   13.65
    6.3. local (specific) tests            
    6.3.1. study of primary (vascular-platelet) hemostasis            
    6.3.1.1. platelet aggregation study            
    6.3.1.1.2. with impedance aggregometers in whole blood, using inducers or ADP or ADP + PGE, or thrombin receptor activating peptide or arachidonic acid            
    6.3.1.1.2.1. screening test (ADF) investigated 2.23 2.23 39.29   41.52
    6.3.1.1.2.1. screening test (TRAP) investigated 2.23 2.23 28.62   30.85
    6.3.2. study of secondary (plasma) hemostasis            
    6.3.2.1. carrying out investigations using multichannel optomechanical automatic hemostasis analyzers            
    6.3.2.1.2. study of secondary plasma hemostasis automated registration of test results (Antithrombin-3) investigated 1.98 1.98 13.92   15.90
    6.3.2.1.2. study of secondary plasma hemostasis automated registration of test results (APTT) investigated 1.98 1.98 2.12   4.10
    6.3.2.1.2. study of secondary plasma hemostasis automated registration of test results (Lupus anticoagulant + confirmatory) investigated 1.98 1.98 52.95   54.93
    6.3.2.1.2. study of secondary plasma hemostasis automated registration of test results (Protein C) investigated 1.98 1.98 18.87   20.85
    6.3.2.1.2. study of secondary plasma hemostasis automated registration of test results (Protein S) investigated 1.98 1.98 32.06   34.04
    6.3.2.1.2. study of secondary plasma hemostasis automated registration of test results (Prothrombin time) investigated 1.98 1.98 2.23   4.21
    6.3.2.1.2. study of secondary plasma hemostasis automated registration of test results (Thrombin time) investigated 1.98 1.98 2.79   4.77
    6.3.2.1.2. study of secondary plasma hemostasis automated registration of test results (Fibrinogen according to Clauss) investigated 1.98 1.98 10.37   12.35
    6.3.2.2. research using semi-automatic optomechanical hemostasis analyzers            
    6.3.2.2.1. screening tests:            
    6.3.2.2.1.1. determination of activated partial thromboplastin time (hereinafter - APTT) investigated 3.69 3.69 1.20   4.89
    6.3.2.2.1.2. extended APTT correction test investigated 3.50 3.50 19.41   22.91
    6.3.2.2.1.5. determination of the content of fibrinogen in blood plasma according to Clauss investigated 3.69 3.69 6.01   9.70
    6.3.2.2.2. custom tests:            
    6.3.2.2.2.1. determination of the activity of the blood coagulation factor or 2, or 5, or 7, or 10, or 8, or 9, or 11, or 12, or 8 in plasma using deficient plasma investigated 3.47 3.47 0.77   4.24
    6.3.2.2.3. circulating anticoagulants            
    6.3.2.2.3.1. physiological anticoagulants:            
    6.3.2.2.3.1 .5. determination of factor Va resistance to activated protein C (factor V anomaly - Leiden) -APC-resistance by clotting method investigated 3.45 3.45 4.08   7.53
    6.3.2.2.3.1 .6. determination of protein S activity            
    6.3.2.2.3.1 .6.2. by immunoturbidimetric method investigated 3.45 3.45 32.14   35.59
    6.3.2.2.3.2. pathological anticoagulants:            
    6.3.2.2.3.2 .1. lupus anticoagulants:            
    6.3.2.2.3.2 .1.1. phospholipid dependent coagulation tests (primary screening):            
    6.3.2.2.3.2 .1.1.1. APTT with lupus-sensitive cephalin investigated 3.45 3.45 1.89   5.34
    6.3.2.2.4. plasmin (fibrinolytic) system:            
    6.3.2.2.4.2. determination of either fibrinogen degradation products (D fragments), or fibrin degradation products (D-dimer)            
    6.3.2.2.4.2 .2. immunoturbidimetric method (DD) (D-dimers) investigated 3.69 3.69 7.84   11.53
    7 Immunoassay            
    7.1. ELISA method (hormones: tumor markers, markers of allergies, antibodies to viral and bacterial antigens, markers of immune status, markers of autoimmune pathology, cytokines, growth factors and other markers in biological fluids            
    7.1.1. Immunological studies ELISA method sample preparation investigated 2.16 2.16 0.36   2.52
    7.1.3. Immunological studies ELISA method automated analysis (17-ОН) investigated 2.79 2.79 0.80   3.59
    7.1.3. Immunological studies ELISA method automated analysis (DEAS) investigated 2.79 2.79 0.83   3.62
    7.1.3. Immunological studies ELISA method automated analysis (ELISA) investigated 2.79 2.79 10.50   13.29
    7.1.3. Immunological studies ELISA method automated analysis (Chlamydia IgA) investigated 2.79 2.79 0.79   3.58
    7.1.3. Immunological studies ELISA method automated analysis (Chlamydia IgG) investigated 2.79 2.79 0.79   3.58
    7.1.4. Immunological studies ELISA method based on strip technologies (LgG to H. pylori) investigated 2.45 2.45 17.31   19.76
    7.1.4. Immunological studies ELISA method based on strip technologies (LgG to rubella virus) investigated 2.45 2.45 8.62   11.07
    7.1.4. Immunological studies ELISA method based on strip technologies (LgG to thyroid peroxidase - ATPO) investigated 2.45 2.45 22.17   24.62
    7.1.4. Immunological studies ELISA method based on strip technologies (LgG to toxoplasma) investigated 2.45 2.45 10.30   12.75
    7.1.4. Immunological studies ELISA method based on strip technologies (LgG to cytomegalovirus) investigated 2.45 2.45 8.99   11.44
    7.1.4. Immunological studies ELISA method based on strip technologies (LgM for rubella virus) investigated 2.45 2.45 10.42   12.87
    7.1.4. Immunological studies ELISA method based on strip technologies (LgM to toxoplasma) investigated 2.45 2.45 11.37   13.82
    7.1.4. Immunological studies ELISA method based on strip technologies (LgM to cytomegalovirus) investigated 2.45 2.45 20.06   22.51
    7.1.4. Immunological studies ELISA method based on strip technologies (Alpha-fetoprotein - AFP) investigated 2.45 2.45 21.17   23.62
    7.1.4. Immunological studies ELISA method based on strip technologies (Vitamin D- (total)) investigated 2.45 2.45 21.94   24.39
    7.1.4. Immunological studies ELISA method based on strip technologies (HIV) investigated 2.45 2.45 7.81   10.26
    7.1.4. Immunological studies ELISA method based on strip technologies (Hepatitis B) investigated 2.45 2.45 15.89   18.34
    7.1.4. Immunological studies ELISA method based on strip technologies (Hepatitis C) investigated 2.45 2.45 16.57   19.02
    7.1.4. Immunological studies ELISA method based on strip technologies (Chorionic Gonadotropin-HCG) investigated 2.45 2.45 16.43   18.88
    7.1.4. Immunological studies ELISA method based on strip technologies (D-dimers) investigated 2.45 2.45 38.51   40.96
    7.1.4. Immunological studies ELISA method based on strip technologies (Cortisol) investigated 2.45 2.45 19.84   22.29
    7.1.4. Immunological studies ELISA method based on strip technologies (Luteinizing hormone -LH) investigated 2.45 2.45 13.71   16.16
    7.1.4. Immunological studies ELISA method based on strip technologies (Oncomarker - CA 125) investigated 2.45 2.45 23.59   26.04
    7.1.4. Immunological studies ELISA method based on strip technologies Oncomarker - CA 19-9) investigated 2.45 2.45 23.58   26.03
    7.1.4. Immunological studies ELISA method based on strip technologies (Antigen determination - CA 15-3) investigated 2.45 2.45 23.64   26.09
    7.1.4. Immunological studies ELISA method based on strip technologies (Progesterone) investigated 2.45 2.45 10.35   12.80
    7.1.4. Immunological studies ELISA method based on strip technologies (Prolactin) investigated 2.45 2.45 17.00   19.45
    7.1.4. Immunological studies ELISA method based on strip technologies (Protein C) investigated 2.45 2.45 19.98   22.43
    7.1.4. Immunological studies ELISA method based on strip technologies (Cancer Embryonic Antigen - CEA) investigated 2.45 2.45 12.54   14.99
    7.1.4. Immunological studies ELISA method based on strip technologies (Free thyroxine - FT4) investigated 2.45 2.45 6.50   8.95
    7.1.4. Immunological studies ELISA method based on strip technologies (Free triiodothyronine - FT3) investigated 2.45 2.45 6.58   9.03
    7.1.4. Immunological studies ELISA method based on strip technologies (Testosterone) investigated 2.45 2.45 15.40   17.85
    7.1.4. Immunological studies ELISA method based on strip technologies (Thyroid stimulating hormone - TSH) investigated 2.45 2.45 7.18   9.63
    7.1.4. Immunological studies ELISA method based on strip technologies (von Willebrandt factor) investigated 2.45 2.45 16.49   18.94
    7.1.4. Immunological studies ELISA method based on strip technologies (Ferritinin) investigated 2.45 2.45 15.74   18,19
    7.1.4. Immunological studies ELISA method based on strip technologies (Follicle-stimulating hormone -FSH) investigated 2.45 2.45 13.71   16.16
    7.1.4. Immunological studies ELISA method based on strip technologies (Estradiol) investigated 2.45 2.45 10.35   12.80
    7.4. immunochromatography method            
    7.4.1. immunophromotography method (express diagnostics) determination in biological fluids (antibodies to SARS-COV-2) China) (Standard test) investigated 2.95 2.95 14.42   17.37
    7.4.1. immunophromotography method (express diagnostics) determination in biological fluids (antibodies to SARS-COV-2) China) (Turkey standard test) investigated 2.95 2.95 17.81   20.76
    7.5. immunohematology            
    7.5.1. determination of blood groups according to the ABO system using isohemaglutinating sera            
    7.5.1.1. in capillary blood investigated 3.91 3.91 1.37   5.28
    7.5.2. determination of blood groups according to the ABO system by a cross method using isohemagglutinating sera and standard erythrocytes            
    7.5.2.2. in venous blood Dia Cla ABO / Rh + AB investigated 3.42 3.42 2.23   5.65
    7.5.3. determination of blood groups by the ABO system and Rh factor using monoclonal reagents            
    7.5.3.1. in capillary blood investigated 3.67 3.67 0.77   4.44
    7.5.3.2. in venous blood investigated 2.93 2.93 0.76   3.69
    7.5.10. Immunohematological studies by gel agglutination            
    7.5.10.1. determination of blood groups by the ABO system by a cross method and the Rh factor in a gel test system using ID-cards on an ID-centrifuge (adult) investigated 1.47 1.47 16.15   17.62
    7.5.10.1. determination of blood groups by the ABO system by a cross method and the Rh factor in a gel test system using ID-cards on an ID-centrifuge (Newborn) investigated 1.47 1.47 8.69   10.16
    7.5.10.2. determination of the phenotype of erythrocytes by antigens of the Rhesus b Kell system in a gel test system using ID cards on an ID centrifuge investigated 1.47 1.47 11.87   13.34
    7.5.10.3. detection of alloimmune anti-erythrocyte antibodies in an indirect antiglobulin test in a gel test system using ID cards on an ID centrifuge investigated 1.96 1.96 9.10   11.06
    7.5.10.4. determination of the specificity of identified alloimmune anti-erythrocyte antibodies in an indirect antiglobulin test in a gel test system using ID cards on an ID centrifuge investigated 6.11 6.11 35.66   41.77
    7.5.10.5. determination of the titer of alloimmune anti-erythrocyte antibodies in an indirect antiglobulin test in a gel test system using ID cards on an ID centrifuge investigated 7.34 7.34 42.60   49.94
    7.5.10.6. detection of anti-erythrocyte antibodies in a direct antiglobulin test (direct Coombs' test) in a gel test system using ID cards on an ID centrifuge investigated 1.96 1.96 3.66   5.62
    7.19. determination of acute phase and specific serum proteins            
    7.19.1. Immunological studies : determination of acute phase and specific proteins by turbidimetric method (CRP) investigated 6.11 6.11 2.89   9.00
    7.26. syphilis diagnostics:            
    7.26.2. precipitation microreaction (hereinafter - MRP) with cardiolipin antigen:            
    7.26.2.1. diagnosis of syphilis: MRP with cardiolipin antigen with inactivated native blood serum -quality method (one in a series) (RW (syphilis)) investigated 1.99 1.99 1.51   3.50
    7.26.3. RPGA with one diagnostic:            
    7.26.3.1. Immunological tests: diagnosis of syphilis RPHA with one diagnosticum - qualitative method (RW) investigated 2.84 2.84 4.43   7.27
    8 Microbiological research            
    8.1. clinical microbiology:            
    8.1.14. Microbiological studies: study on urea, mycoplasma in the discharge of the genitourinary organs, urine, sputum using commercial test systems without sampling in the laboratory (Ureamikoplasma) investigated 2.20 2.20 19.88   22.08

     

    The cost of materials and medicines required for the procedures is calculated at current prices, based on the approved consumption rates for medicines and materials.





    Reviews

    Marina

    Friends advised to sign up for an ultrasound scan and courses on preparation for childbirth at the maternity hospital at the address: Minsk, F. Skorina 16. Good attitude of the medical staff, the information on the courses is very useful.

    Sevryukova Olga Viktorovna

    I express my deep gratitude to the midwife of the maternity ward, Malevich Svetlana Nikolaevna. Only thanks to your qualifications, skills and abilities, my child was born.

    Olga

    Friends advised me to seek advice from a gynecologist at the regional maternity hospital. I signed up through paid services, I'm very pleased with the good attitude, got appointments, I'm recovering.

    Mila

    Regional maternity hospital, doctor Shmak K.I. She gave birth in August. I am grateful with all my heart and soul to the entire team of professionals who accompanied me from the moment of birth to discharge!

    Anastasia

    Gave birth in October 2019. Is free. Medvedev's doctor is from God. Insanely happy that it was in this hospital that I gave birth. There were partner births.

    Julia

    Gave birth on April 7, 2020. Free, but the attitude was as paid. Very cozy and comfortable. They explained everything and helped. I was very pleased.

    Vera

    End of November, free delivery. The best impressions. Low bow to all the staff and deep gratitude for the attitude towards women in labor and children and the incredible humanity with which everyone works there.

    Katerina

    July. Free delivery. Doctors, obstetricians, neonatologists and everything is at the highest level. Full information about everything. And yes, there were interns all the time. It was all worth it !!! Doctors from God, grateful with all my soul!

    Julia

    Excellent maternity hospital, helpful staff. Some positive impressions.

    Victoria

    The maternity hospital exceeded my expectations !!! Anyone who is relevant - only here I advise you to go to give birth! The professionalism and friendliness of the doctors are just at their best! Everything in the maternity hospital is modern, not like in the USSR !!!